Heparin for assisted reproduction

Cochrane Database of Systematic Reviews

Volumn 2013, Issue 8, 2013, Pages

  Akhtar, Muhammad A ^a   Sur, Shyamaly ^b   Raine Fenning, Nick ^b   Jayaprakasan, Kannamannadiar ^b   Thornton, Jim G ^c   Quenby, Siobhan ^d  

^a UNIVERSITY HOSPITALS COVENTRY AND WARWICKSHIRE NHS TRUST   (United Kingdom)

^b UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^c UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^d UNIVERSITY OF WARWICK   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; PLACEBO; ANTICOAGULANT AGENT;

ALLERGIC REACTION; BIRTH RATE; BLEEDING; CLINICAL OUTCOME; ECCHYMOSIS; FEMALE SUBFERTILITY; FIRST TRIMESTER PREGNANCY; HEPARINIZATION; HUMAN; IN VITRO FERTILIZATION; INFERTILITY THERAPY; INJECTION SITE CONTUSION; INTRACYTOPLASMIC SPERM INJECTION; INTRAUTERINE GROWTH RETARDATION; LIVE BIRTH; MATERNAL BLEEDING; MATERNAL HYPERTENSION; MULTIPLE PREGNANCY; PLACENTA PREVIA; PREECLAMPSIA; PREGNANCY COMPLICATION; PREGNANCY RATE; PREMATURE LABOR; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SECOND TRIMESTER PREGNANCY; SOLUTIO PLACENTAE; SPONTANEOUS ABORTION; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; DRUG ADMINISTRATION; EMBRYO TRANSFER; FEMALE; META ANALYSIS; NIDATION; PREGNANCY;

ANTICOAGULANTS; BIRTH RATE; DRUG ADMINISTRATION SCHEDULE; EMBRYO IMPLANTATION; EMBRYO TRANSFER; FEMALE; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; LIVE BIRTH; PREGNANCY; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REPRODUCTIVE TECHNIQUES, ASSISTED;

EID: 84893380794     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD009452.pub2     Document Type: Review

References (43)

1. Noci I, Milanini MN, Ruggiero M, Papini F, Fuzzi B, Artini PG. Effect of dalteparin sodium administration on IVF outcome in non-thrombophilic young women: a pilot study. Reproductive BioMedicine Online June 2011;22(6):615-20.
2. Qublan H, Amarin Z, Dabbas M, Farraj AE, Beni-Merei Z, Al-Akash H, et al. Low-molecular-weight heparin in the treatment of recurrent IVF-ET failure and thrombophilia: A prospective randomized placebo-controlled trial. Human Fertility December 2008;11(4):246-53.
3. Urman B, Ata B, Yakin K, Alatas C, Aksoy S, Mercan R, et al. Luteal phase empirical low molecular weight heparin administration in patients with failed ICSI embryo transfer cycles: a randomized open-labeled pilot trial. Human Reproduction April 2009;24(7):1640-7.
4. Berker B, Taşkin S, Kahraman K, Taşkin EA, Atabekoglu C, Sönmezer M. The role of low-molecular-weight heparin in recurrent implantation failure: a prospective, quasi-randomized, controlled study. Fertility and Sterility June 30, 2011;95(8):2499-502.
5. Colicchia, A Pergolini I, Gilio B, Rampini MR, Alfano P, Marconi D, et al. Role of heparin in embryo implantation in women without thrombophilia: A pilot study. 27th Annual Meeting of the European Society of Human Reproduction and Embryology, ESHRE 2011 Stockholm Sweden. Conference Publication. July 2011; Vol. 26:pp i157.
6. Stern C, Chamley L, Norris H, Hale L, Baker HWG. A randomized, double-blind, placebo controlled trial of heparin and aspirin for women with in vitro fertilization implantation failure and antiphospholipid or antinuclear antibodies. Fertility and Sterility August 2003;80(2):376-83.
7. Mashayekhy M, Dehghani Firouzabadi R Ghasemi N. The effect of heparin in treatment of recurrent IVF-ET failure. Iranian Journal of Reproductive Medicine Spring 2011;9 (Suppl 2):30.
8. Arai T, Parker A, Busby W Jr, Clemmons DR. Heparin, heparan sulfate, and dermatan sulfate regulate formation of the insulin-like growth factor-I and insulin-like growth factor-binding protein complexes. Journal of Biological Chemistry 1994;269:20388-93.
9. Bick RL, Frenkel EP, Walenga J, Fareed J, Hoppensteadt DA. Unfractionated heparin, low molecular weight heparins, and pentasaccharide: basic mechanism of actions, pharmacology and clinical use. Hematology Oncology Clinics of North America 2005;19:1-51.
10. Bohlmann MK. Effects and effectiveness of heparin in assisted reproduction. Journal of Reproductiv Immunology 2011 Jun;90(1):82-90.
11. Comper WD. Heparin (and Related Polysaccharides) Structural and Functional Properties. Gordon and Breach Publication Group, 1981.
12. Corvinus FM, Fitzgerald JS, Friedrich K, Markert UR. Evidence for a correlation between trophoblast invasiveness and STAT3 activity. American Journal of Reproductive Immunology 2003;50:316-21.
13. Di Simone N, Di Nicuolo F, Sanguinetti M, Ferrazzani S, D'Alessio MC, Castellani R, et al. Low-molecular weight heparin induces in vitro trophoblast invasiveness: role of matrix metalloproteinases and tissue inhibitors. Placenta 2007;28(4):298-304.
14. D'Souza SS, Daikoku T, Farach-Carson MC, Carson DD. Heparanase expression and function during early pregnancy in mice. Biology of Reproduction 2007;77:433-41.
15. Egger M, Smith GD, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;31(7109):629-34.
16. Erden O, Imir A, Guvenal T, Muslehiddinoglu A, Arici S, Cetin M, et al. Investigation of the effects of heparin and low molecular weight heparin on E-cadherin and laminin expression in rat pregnancy by immunohistochemistry. Human Reproduction 2006;21:3014-8.
17. Fluhr H, Spratte J, Ehrhardt J, Steinmüller F, Licht P, Zygmunt, M. Heparin and low-molecular-weight heparins modulate the decidualization of human endometrial stromal cells. Fertility and Sterility 2010;93:2581-7.
18. Germeyer A, Klinkert MS, Huppertz AG, Clausmeyer S, Popovici RM, Strowitzki T, et al. Expression of syndecans, cell-cell interaction regulating heparan sulfate proteoglycans, within the human endometrium and their regulation throughout the menstrual cycle. Fertility and Sterility 2007;87(3):657-63.
19. Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Intervention Version 5.1.0. The Cochrane Collaboration. Available from www.cochrane-handbook.org 2011.
20. Kelly FD, Tawia SA, Rogers PAW. Physiology: immunohistochemical characterization of human endometrial microvascular basement membrane components during the normal menstrual cycle. Human Reproduction 1995;10(2):268-76.
21. Kutteh WH, Yetman DL, Chantilis SJ, Crain J. Effect of antiphospholipid antibodies in women undergoing in-vitro fertilization: role of heparin and aspirin. Human Reproduction 1997;12(6):1171-5.
22. Lai TH, King JA, Shih IeM, Vlahos NF, Zhao Y. Immunological localization of syndecan-1 in human endometrium throughout the menstrual cycle. Fertility and Sterility 2007;87(1):121-6.
23. Leach RE, Kilburn B, Wang J, Liu Z, Romero R, Armant DR. Heparin-binding EGF-like growth factor regulates human extravillous cytotrophoblast development during conversion to the invasive phenotype. Developmental Biology 2004;266:223-37.
24. Lodigiani C, Di Micco P, Ferrazzi P, Librè L, Arfuso V, Polatti F, et al. Low-molecular-weight heparin in women with repeated implantation failure. Womens Health (Lond Engl) 2011 Jul;7(4):425-31.
25. Moller AV, Jorgensen SP, Chen JW, Larnkjaer A, Ledet T, Flyvbjerg A, et al. Glycosaminoglycans increase levels of free and bioactive IGF-I in vitro. European Journal of Endocrinology 2006;155:297-305.
26. Murray WJ, Lindo VS, Kakkar VV, Melissari E. Long-term administration of heparin and heparin fractions and osteoporosis in experimental animals. Blood Coagulation & Fibrinolysis 1995;6:113-8.
27. Nardo LG, Granne I, Stewart J. Policy & Practice Committee of the British Fertility Society. Medical adjuncts in IVF: evidence for clinical practice. Human Fertility 2009 Mar;12(1):1-13.
28. Nelson SM, Greer IA. The potential role of heparin in assisted conception. Human Reproduction Update 2008;14:623-45.
29. Poehlmann TG, Fitzgerald JS, Meissner A, Wengenmayer T, Schleussner E, FriedrichK, et al. Trophoblast invasion: tuning through LIF, signalling via Stat3. Placenta 2005;26 Suppl:37-41.
30. Potter SW, Morris JE. Changes in histochemical distribution of cell surface heparan sulfate proteoglycan in mouse uterus during the estrous cycle and early pregnancy. Anatomical Record 1992;234:383-90.
31. The Practice Committee of the American Society for Reproductive Medicine. Anti-phospholipid antibodies do not affect IVF success. Fertility and Sterility 2008;90(3):S172-S173.
32. Quenby S, Mountfield S, Cartwright JE, Whitley GS, Vince G. Effects of low-molecular-weight and unfractionated heparin on trophoblast function. Obstetrics & Gynecology 2004;104:354-61.
33. Ricci G, Giolo E, Simeone R. Heparin's potential to improve pregnancy rates and outcomes' is not evidence based. Human Reproduction Update 2010;16:225-7.
34. San Martin S, Soto-Suazo M, Zorn TMT. Perlecan and syndecan-4 in uterine tissues during the early pregnancy in mice. American Journal of Reproductive Immunology 2004;52:53-9.
35. Sharif KW, Ghunaim S. Management of 273 cases of recurrent implantation failure: results of a combined evidence-based protocol. Reproductive BioMedicine Online 2010;21:373-80.
36. Sher G, Feinman M, Zouves C, Kuttner G, Maassarani G, Salem R, et al. High fecundity rates following in-vitro fertilization and embryo transfer in antiphospholipid antibody seropositive women treated with heparin and aspirin. Human Reproduction 1994;9:2278-83.
37. Sher G, Matzner W, Feinman M, Maassarani G, Zouves C, Chong, P, et al. The selective use of heparin/aspirin therapy, alone or in combination with intravenous immunoglobulin G, in the management of antiphospholipid antibody-positive women undergoing in vitro fertilization. American Journal Reproductive Immunology 1998;40:74-82.
38. Vail A, Gardener E. Common statistical errors in the design and analysis of subfertility trials. Human Reproduction 2003;18:1000-4.
39. Wang L, Brown JR, Varki A, Esko JD. Heparin's anti-inflammatory effects require glucosamine 6-O-sulfation and are mediated by blockade of L- and P-selectins. Journal of Clinical Investigation 2002;110:127-36.
40. Warkentin TE, Levine MN, Hirsh J, Horsewood P, Roberts RS, Gent M, et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. New England Journal of Medicine 1995;332:1330-5.
41. Warkentin TE, Greinacher A. Heparin-induced thrombocytopenia: recognition, treatment, and prevention: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126 Suppl:311-37.
42. Weigert C, Brodbeck K, Haring HU, Gambaro G, Schleicher ED. Low-molecular-weight heparin prevents high glucose- and phorbol ester-induced TGF-beta 1 gene activation. Kidney International 2001;60:935-43.
43. Xu X, Ding J, Rao G, Shen J, Prinz RA, Rana N, et al. Estradiol induces heparanase-1 expression and heparan sulphate proteoglycan degradation in human endometrium. Human Reproduction 2007;22:927-37.